Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: Bonefish who wrote (1219420)	4/11/2020 4:44:10 PM
From: locogringo	2 Recommendations Recommended By Bonefish Winfastorlose Respond to of 1582285

If you get covid...go ahead and refuse treatment until the double blind study is finished. Be my guest. Can my family and relatives have his share? I'll gladly pay for shipping.

To: Bonefish who wrote (1219420)	4/11/2020 6:31:12 PM
From: SeachRE	2 Recommendations Recommended By pocotrader sylvester80 Read Replies (1) \| Respond to of 1582285

A Shanghai HOCQ study as well as other French studies were not that impressive...these hospitalized CV19 patients are often very fragile(dehydration,low oxygen, failing kidneys and heart), unlike your average arthritis or lupus patients. There have been a few reports of serious heart toxicity here. OTOH, Gilead's Remdesevir came out with impressive numbers for patients with "severe disease" this AM, but the authors acknowledged the need for large RCTs still. RCT results will be available in a few weeks. So, things are moving...just because Trump says HOCQ is "a game changer" it doesn't have to be.